New 'Gene-Silencing' drug enters first human tests for fatal lung disease
NCT ID NCT07407543
Summary
This is a very early study to check the safety of a new drug called SRN001, which is being developed to treat a serious lung scarring disease called idiopathic pulmonary fibrosis. The study will give the drug to 30 healthy Korean and Caucasian men to see how their bodies react to it, how it moves through their system, and what side effects might occur. The main goal is not to treat the disease yet, but to gather the first safety data needed before testing in patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.